Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys
- PMID: 22438471
- PMCID: PMC3362877
- DOI: 10.1124/jpet.112.193078
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys
Abstract
This study examined mechanisms by which nicotine (1.78 mg/kg base s.c.) produces discriminative stimulus effects in rhesus monkeys. In addition to nicotine, various test compounds were studied including other nicotinic acetylcholine receptor agonists (varenicline and cytisine), antagonists [mecamylamine and the α4β2 receptor-selective antagonist dihydro-β-erythroidine (DHβE)], a nicotinic acetylcholine receptor antagonist/indirect-acting catecholamine agonist (bupropion), and non-nicotinics (cocaine and midazolam). Nicotine, varenicline, and cytisine dose-dependently increased drug-lever responding; the ED(50) values were 0.47, 0.53, and 39 mg/kg, respectively. Bupropion and cocaine produced 100% nicotine-lever responding in a subset of monkeys, whereas mecamylamine, DHβE, and midazolam produced predominantly vehicle-lever responding. The training dose of nicotine resulted in 1128 ng/ml cotinine in saliva. Mecamylamine antagonized the discriminative stimulus effects of nicotine and varenicline, whereas DHβE was much less effective. Nicotine and varenicline had synergistic discriminative stimulus effects. In monkeys responding predominantly on the vehicle lever after a test compound (bupropion, cocaine, and midazolam), that test compound blocked the nicotine-discriminative stimulus, perhaps reflecting a perceptual-masking phenomenon. These results show that nicotine, varenicline, and cytisine produce discriminative stimulus effects through mecamylamine-sensitive receptors (i.e., nicotinic acetylcholine) in primates, whereas the involvement of DHβE-sensitive receptors (i.e., α4β2) is unclear. The current nicotine-discrimination assay did not detect a difference in agonist efficacy between nicotine, varenicline, and cytisine, but did show evidence of involvement of dopamine. The control that nicotine has over choice behavior can be disrupted by non-nicotinic compounds, suggesting that non-nicotinics could be exploited to decrease the control that tobacco has over behavior.
Figures
References
-
- Buchhalter AR, Fant RV, Henningfield JE. (2008) Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68:1067–1088 - PubMed
-
- Chandler CJ, Stolerman IP. (1997) Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology 129:257–264 - PubMed
-
- Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477 - PubMed
-
- Dale HH. (1914) The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 6:147–190
-
- de la Garza R, Johanson CE. (1982) Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav 17:1295–1299 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
